Dr. Loeffler

Dr. Löffler

Dr. med. Dipl. Biol. Bernd-Michael Loeffler

Practicing doctor, scientific head

Dr. Loeffler is the scientific director at AgeLine® and a renowned researcher in medicine, biology and biochemistry. His publications and lectures in the field of preventive and mitochondrial medicine are the basis of innovative treatment methods for various diseases, including metabolic disorder and related skin diseases. After 9 years of research at the Max Planck Institute for Experimental Medicine, Dr. Loeffler spent 16 years in research at a leading pharmaceutical company and played a leading role in the development of new medicines.

In 2005 he founded his first institute with a medical practice in Berlin-Charlottenburg. Since then, his patients kept asking not only how to live a longer and healthier life, but also how to keep a youthful appearance. This inspired Dr. Loeffler to create AgeLine®. Today Dr. Loeffler´s Institute for Mitochondrial Medicine takes a holistic approach in the anti-aging area and specializes in preventively decelerating the aging process, as well as increasing physical well-being, inner balance and external attractiveness.

Dr. Löffler gründete 2005 sein Institut

Current position 

  • Practicing doctor specialized in mitochondrial and preventive medicine
  • AGMID president
  • book author and author of numerous publications
  • Holder of more than 50 international patents

Patient clientele 

  • Patients from all over the world
  • Cancer patients
  • Patients with various vitamin and mineral deficiencies
  • Patients with chronic diseases – e.g.: Chronique Fatigue Syndrom (DFS), lyme disease, inflammatory diseases

Key positions 

  • Doctor and researcher in medicine, biology & biochemistry with 4 decades of experience
  • 9 years at the Max Planck Institute for Experimental Medicine
  • 16 years of research and development of new drugs at a leading pharmaceutical company
  • Since 2005 own research institute and practice in Berlin

The AgeLine® approach:
Applied mitochondrial medicine

AgeLine® is a highly effective, perfectly balanced skincare series which is based on two modern areas of medical science. AgeLine® combines the most effective cosmetic ingredients with modern transport technologies of medicine. This optimizes the absorption of the ingredients, alleviates existing signs of skin aging and prevents the emergence of new ones.

Dr. Löffler entwickelt eine optimierte Pflegeserie
Professional background
  • 1975 – 1985 – study of human medicine, biology, chemistry and physics at the Georg-August -University of Goettingen
  • 1981 – diploma in Biology with focus on biochemistry, summa cum laude
  • 1986 – Doctorate in medicine, summa cum laude
  • 1978 – 1980 – scientific assistant at the Institute for Plant Biochemistry at the University of Goettingen, deputy head PD. Dr. Harnischfeger
  • 1980 – 1984 – scientific assistant at the Max-Planck-Institute for Experimental Medicine, working group Prof. Dr. H. Kunze, department Prof. Dr. W. Vogt
  • 1985 – 1989 – research associate at the Max-Planck-Institute for Experimental Medicine, working group Prof. Dr. H. Kunze, department Prof. Dr. W. Vogt
  • 1988 – guest professorship at the University of Edmonton, Canada, working group Prof. Dr. D.N. Brindley
  • 1989 – 2005 – Preclinical research F. Hoffmann-La Roche (Basel) since 2002 in the position of Vice Director
  • 2003 – 2004 – training in men´s medicine at HOMMAGE
  • since 2004 – continued education in orthomolecular and preventive medicine
  • 1989 – 2000 – Cardiovascular diseases, SAH (Subarachniodal Hemorrhage)
  • 2000 – 2005 – metabolic diseases (focus: Type II diabetes, Metanolic syndrome)

drug development 
Essentially involved in the development of two drugs:

  • Tracleer (bosentan) for PAH (pulmonary arterial hypertension)
  • SPP301 for diabetic nephropathy (as of December 2006 fast track status conferred
  • April 2005 – founding of Loeffler Consulting in Zug (Switzerland), providing scientific advice to researching pharmaceutical companies (e.g. F.Hoffmann-La Roche, Santhera, Biovitrum)
  • May 2005 – Founding IPAM (Institute for Prevention and Anti-Aging Medicine) development of medical products, lectures, preventive medical education
  • December 2006 – appointed to the Scientific Advisory Board of Santhera Pharmaceuticals AG
  • February 2007 – private practice for preventive medicine
  • since dec. 2006 – member of the Scientific Advisory Board of Santhera Pharmaceuticals

Main research areas: tertosterone biosynthesis regulation, lysosomal phospholipid metabolism, renin-angiotensin system, endothelin system, dipeptidyl peptidase IV


  • 77 publications, 50 international patents, more than 200 lectures and congress contributions
  • Expert activities
  • DFG, ÖFG, Hypertension, FEBS


  • German Chemical Society
  • German Society for Biochemistry and Molecular Biology
  • Forum Orthomolecular Medicine
  • German Society for Preventive Medicine
  • German Society for Anti-Aging Medicine
  • American Association for Anti-Aging Medicine
  • American Heart Association, American Diabetes Association
  • and others